Reference (Jul-20-A4)
1. (Colbert et al., 2020; Gillim-Ross and Subbarao, 2006; Ma et al., 2020; Oyston and Robinson, 2012; Sauerwein et al., 2011; Siegrist, 2007;
Webster et al., 2005)
2. Chen, H.W., Huang, C.Y., Lin, S.Y., Fang, Z.S., Hsu, C.H., Lin, J.C., Chen, Y.I., Yao, B.Y., and Hu, C.M. (2016).
3. Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection.
Biomaterials 106, 111-118.
4. Colbert, L.E., Kouzy, R., Abi Jaoude, J., Ludmir, E.B., and Taniguchi, C.M. (2020). Cancer Research after COVID-19: Where Do We Go
from Here? Cancer cell 37, 637-638.
5. Gillim-Ross, L., and Subbarao, K. (2006). Emerging respiratory viruses: challenges and vaccine strategies. Clinical microbiology reviews
19, 614-636.
6. Huisman, W., Martina, B.E., Rimmelzwaan, G.F., Gruters, R.A., and Osterhaus, A.D. (2009). Vaccine-induced enhancement of viral
infections. Vaccine 27, 505-512.
7. Ma, Z., Liu, J., and Pan, Q. (2020). Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. Trends in
pharmacological sciences.
8. Oyston, P., and Robinson, K. (2012). The current challenges for vaccine development. Journal of medical microbiology 61, 889-894.
9. Sauerwein, R.W., Roestenberg, M., and Moorthy, V.S. (2011). Experimental human challenge infections can accelerate clinical malaria
vaccine development. Nature reviews Immunology 11, 57-64.
10. Siegrist, C.A. (2007). The challenges of vaccine responses in early life: selected examples. Journal of comparative pathology 137 Suppl 1,
S4-9.
11. Webster, D.P., Dunachie, S., Vuola, J.M., Berthoud, T., Keating, S., Laidlaw, S.M., McConkey, S.J., Poulton, I., Andrews, L., Andersen,
R.F., et al. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and
modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America 102, 4836-4841.
